...
首页> 外文期刊>European Journal of Medicinal Chemistry: Chimie Therapeutique >Discovery of novel arylethenesulfonyl fluorides as potential candidates against methicillin-resistant of Staphylococcus aureus (MRSA) for overcoming multidrug resistance of bacterial infections
【24h】

Discovery of novel arylethenesulfonyl fluorides as potential candidates against methicillin-resistant of Staphylococcus aureus (MRSA) for overcoming multidrug resistance of bacterial infections

机译:发现新型芳基乙烯磺酰氟化氟化物作为抗甲氧吡喃金黄色葡萄球菌(MRSA)的潜在候选物,用于克服细菌感染的多药抗性

获取原文
获取原文并翻译 | 示例

摘要

The multidrug-resistant Staphylococcus aureus (MRSA) is one of the most prevalent human pathogens involved in many minor to major disease burdens throughout the world. Inhibition of biofilm formation is an attractive strategy to treat diseases associated with MRSA infection. In the present investigation, a series of functional group diverse (hetero)aryl fluorosulfonyl analogs were designed, synthesized and tested as antibacterial agents against Staphylococcal spp., and as anti-biofilm candidates. Compounds 8, 15, and 67 were found to possess potent in vitro antibacterial activity among this class of sulfonyl fluorides (MIC = 0.818 +/- 0.42, 0.840 +/- 0.37 and 0.811 +/- 0.37 mu g/mL respectively). The analogs 8, 15, 36, and 67 exhibited outstanding anti-biofilm properties compared to other available synthetic antibiotics. The efficacy of synthetic analogs displayed membrane-damaging effect and they are also validated by cellular content release assay. The insight physiological changes were explored by studying the intracellular redox activities through changing cyclic voltammetric (CV) method. The compounds 8,15, 22, 32, 36, 51, and 67 were found to participate in the interfering in the electron transport chain (ETC) of MRSA. The analogs 8, 15, and 67 possess great potentiality for discovery and development of anti-staphylococcal drugs to treat the MRSA infections. (C) 2018 Elsevier Masson SAS. All rights reserved.
机译:多药抗性金黄色葡萄球菌(MRSA)是涉及许多患有全球主要疾病繁殖的众多人群的最普遍的人类病原体之一。抑制生物膜形成是一种吸引与MRSA感染相关的疾病的有吸引力的策略。在本研究中,设计了一系列官能团的官能团(杂)芳基氟磺酰基类似物,合成和测试为抗葡萄球菌SPP的抗菌剂,并作为抗生物膜候选者。发现化合物8,15和67在这类磺酰氟化物中具有有效的体外抗菌活性(MIC = 0.818 +/- 0.42,0.840 +/- 0.37和0.811 +/-0.37μg/ ml)。与其他可用的合成抗生素相比,类似物8,15,36和67表现出优异的抗生物膜特性。合成类似物显示膜损伤效果的功效,并且通过细胞含量释放测定还验证它们。通过改变循环伏安法(CV)方法,通过研究细胞内氧化还原活性来探索洞察力生理变化。发现化合物8,15,22,32,36,51和67参与MRSA的电子传输链(ETC)中的干扰。模拟8,15和67具有巨大的发现和开发抗葡萄球菌药物以治疗MRSA感染的巨大潜力。 (c)2018年Elsevier Masson SAS。版权所有。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号